Novo Nordisk’s UK unit has been suspended as a member of the Association of the British Pharmaceutical Industry (ABPI) for two years due to what was described as “serious breaches” of the ...

Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal. The Danish ...